The theme of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting is "The art and science of cancer care:from comfort to cure." Extensive research was presented on the hormonal receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative subtype of metastatic breast cancer. Three late-breaking abstracts (LBA) reported the latest findings of the post MONARCH (LBA1001),Young-PEARL (LBA1002),and SACI-IO HR+(LBA1004) studies,generating significant interest. In this paper,we present a compre-hensive review of the progress on HR+/HER2-metastatic breast cancer treatment research as reported at this annual meeting.

The theme of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting is "The art and science of cancer care:from comfort to cure." Extensive research was presented on the hormonal receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative subtype of metastatic breast cancer. Three late-breaking abstracts (LBA) reported the latest findings of the post MONARCH (LBA1001),Young-PEARL (LBA1002),and SACI-IO HR+(LBA1004) studies,generating significant interest. In this paper,we present a compre-hensive review of the progress on HR+/HER2-metastatic breast cancer treatment research as reported at this annual meeting.